市場調查報告書
商品編碼
925256

乳癌液態切片市場 - 成長,趨勢,預測

Breast Cancer Liquid Biopsy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

預計全球乳癌液態切片市場在2020年∼2025年間,預測將以18.9%多的年複合成長率擴大。乳癌的盛行率的上升和,對更微創的治療方法的需求的增加帶動市場。

本報告提供乳癌液態切片的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊 。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各循環生物標記
    • 循環腫瘤細胞(CTC)
    • 循環無細胞DNA(cfDNA)
    • 細胞外小胞
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • QIAGEN
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories Inc
    • Janssen Diagnostics
    • Biocept Inc
    • Guardant Health, Inc
    • Myriad Genetics
    • Adaptive Biotechnologies
    • Epic Sciences
    • Illumina, Inc

第7章 市場機會及未來趨勢

目錄
Product Code: 67698

The Breast Cancer Liquid Biopsy Market is poised to grow at a CAGR of 14.5% by 2026.

The COVID-19 pandemic is expected to have a negative effect on market growth. The pandemic had brought several adverse impacts on breast cancer biopsy services. Hospitals, clinics, and diagnostic centers were unable to provide biopsy services, due to lockdown situations across some countries to prevent the spread of COVID-19. In a study conducted in the United Kingdom and published in The Lancet Oncology in March 2021, the consequences of delayed diagnosis of cancer due to COVID-19 were researched upon. Data from over 100,000 patients with breast, colorectal, esophageal, or lung cancer were evaluated in the study. The study showed that 1 and 5-year survival rates due to cancer will significantly reduce due to the pandemic because of the lack of access to screening services. Thus, as lockdowns drag on, and screening services get affected, survivability due to cancer will decrease.

Increase in regulatory approvals are expected to have a positive effect on the market. For example, in June 2019, the United States Food and Drug Administration (FDA) provided regulatory approval to QIAGEN's therascreen PIK3CA RGQ PCR Kit. The approval was granted with the device's use as a companion diagnostic assay to detect PIK3CA mutations in breast cancer for both tissue and liquid biopsies.

For the detection of breast cancer, traditional methods like tissue biopsies are not comprehensive enough to predict or capture the entire genomics landscape of breast tumors. Liquid biopsy as an alternative method for the detection of breast cancer, allows for many clinical applications, that include screening, therapy selection, detection of mutations, disease prognosis and drug response and resistance in patients who are unable to undergo an invasive tumor biopsy. Liquid biopsies provide unique benefits as compared with other genetic testing methods, such as collecting samples with tumor biopsies. Collecting samples from the blood is a comparatively less invasive procedure and can provide a better understanding of cancer. Usually, taking a biopsy from one side of a tumor, rather than the other, may impact the accuracy of the results, which does not happen with liquid biopsies. Additionally, a major advantage of liquid biopsy involves the possibility to detect a tumor smaller than the ones detectable by traditional screening based on imaging techniques. In fact, liquid biopsy can analyze cancer DNA, not its mass, enabling earlier tumor diagnosis.

One of the major factors leading to market growth is the global increase in breast cancer cases. According to World Health Organization (WHO), across the globe, breast cancer is the most frequent type of cancer among women. Approximately 2.1 million women suffer from breast cancer every year, and it leads to highest number of cancer-related deaths among women. In the year 2018, it was estimated that approximately 627,000 women died from breast cancer which represented nearly 15% of all cancer deaths among women globally. According to Breast Cancer Care WA Incorporated, it was estimated that in 2019, 19,371 Australian women were diagnosed with breast cancer or approximately 53 each day, which accounts for approximately 14% of all new cancer cases diagnosed. Furthermore, according to Cancer Research UK, breast cancer is the most common cancer in the United Kingdom, accounting for 15% of all the new cancer cases. High prevalence of breast cancer and increasing demand for better minimally invasive therapies are the major driving factors in the breast cancer liquid biopsy market.

Key Market Trends

Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share in the Breast Cancer Liquid Biopsy Market

Circulating cell-free DNA (cfDNA) in plasma offers a non-invasive approach to monitor tumor molecular profiling in real-time at multiple time-points, detection of emerging genomic alterations associated with drug resistance, and clarifying cancer prognosis and diagnosis of cancer recurrence or progression. There are many companies that offer cfDNA based products for use in research purposes. For example, Hilden, Germany-based Qiagen offers the QIAamp circulating nucleic acid kit that is used in a column-based method to isolate cfDNA from plasma and serum. Genomics For Life Pty Ltd is a Queensland, Australia-based company that offers genetic testing for cfDNA from blood samples. It is a major private-sector company that provides cfDNA-based testing services in Australia.

According to the World Health Organization (WHO), in the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally. Due to technological advancements in breast cancer liquid biopsy, the circulating cell-free DNA segment is anticipated to show significant development. Bio-Rad Laboratories Inc offers the 'QX200 Droplet Digital PCR (ddPCR)' system which provides absolute quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications. In addition, the recent innovations leading to the introduction of better and more sensitive screening techniques (like ddPCR), has permitted the quantification and detection of low abundance targets in shorter times without requiring large numbers of replicates. This has established ddPCR as a tool of choice for liquid biopsies which is being utilized fir breast cancer diagnosis. These developments are expected to fuel market growth during the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The North America region is expected to hold a major market share in the global breast cancer liquid biopsy market. This is primarily due to rising incidences of breast cancer and the growing demand for non-invasive treatment in this region.

According to the National Breast Cancer Foundation of the United States, in the year 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represented approximately 15.2% of all new cancer cases in the United States. In the United States, Biocept, a molecular oncology diagnostics company, offers advanced methods for detecting circulating cancer cells (CTCs) and oncogene mutation fragments (ctDNA) in the blood. This allows CLIA-certified and CAP-accredited laboratories to perform predictive biomarker testing and provide the most up-to-date biomarker status from a non-invasive patient blood sample in breast cancer diagnosis, opening up opportunities in breast cancer liquid biopsy.

In July 2020, a group led by Canada-based Canexia Health launched a USD 1.9 million liquid biopsy screening initiative that aimed to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic. Initiatives like these are expected to affect market development in a positive manner.

Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Breast Cancer Liquid Biopsy Market is slightly fragmented and competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are QIAGEN, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Janssen Diagnostics, Biocept Inc, Guardant Health, Inc, Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences, Inc., Biodesix and Illumina, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Breast Cancer
    • 4.2.2 Increasing Demand for Better Minimally Invasive Therapies
    • 4.2.3 Technological Advancements in the Early Stage Detection of Breast Cancer
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Circulating Biomarkers
    • 5.1.1 Circulating Tumor Cells (CTCs)
    • 5.1.2 Circulating cell-free DNA (cfDNA)
    • 5.1.3 Extracellular Vesicles
    • 5.1.4 Other Circulating Biomarkers
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Qiagen
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 Bio-Rad Laboratories Inc
    • 6.1.4 Janssen Diagnostics
    • 6.1.5 Biocept Inc
    • 6.1.6 Guardant Health, Inc
    • 6.1.7 Myriad Genetics
    • 6.1.8 Adaptive Biotechnologies
    • 6.1.9 Epic Sciences
    • 6.1.10 Illumina, Inc
    • 6.1.11 Fluxion Biosciences, Inc.
    • 6.1.12 Biodesix
    • 6.1.13 Pathway Genomics (OME Care)
    • 6.1.14 Exosome Diagnostics, Inc.
    • 6.1.15 PapGene

7 MARKET OPPORTUNITIES AND FUTURE TRENDS